Navigation Links
The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
Date:10/5/2009

LAUSANNE, Switzerland, October 5 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and the Japanese Cancer Association (JCA) presented 'The JCA-Mauvernay Award' to Dr Toshikazu Ushijima from the National Cancer Center Research Institute in Tokyo, for his outstanding and innovative research in basic science in the "epigenetic field for cancerization". The ceremony took place on October 3rd, during the General Assembly of the 68th Annual Conference of the JCA in Japan, where Professor Setsuo Hirohashi, President of the JCA and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group presented him with the Award.

Since 1999, Dr Toshikazu Ushijima has headed the Carcinogenesis Division at the National Cancer Center Research Institute. His basic research focuses on the establishment of a novel concept referred to as "epigenetic field for cancerization, its mechanistic clarification, and its potential clinical application". He demonstrated that aberrant DNA methylation, the most common molecular lesion of the cancer cell, accumulated in surrounding non-cancerous tissue of cancer patients, and that there is a correlation between this accumulation and the risk of cancer development. He also demonstrated that Helicobacter pylori infection, a potent gastric carcinogenic factor, induces aberrant DNA methylation in gastric mucosa. In recent studies, Dr Ushijima showed that the suppression of inflammation with an immunosuppressive drug leads to the suppression of DNA methylation induced by Helicobacter pylori infection. He has also initiated a prospective study to use DNA methylation levels in gastric mucosa as a risk marker for metachronous gastric cancers following endoscopic mucosal dissection. The finding in the stomach is likely to be expanded to colorectal, esophageal, liver, breast, and renal cancers, in which the individuals' life style can produce predisposed field for cancers in a normal-appearing tissue.

"We are proud to reward Dr Ushijima for his innovative work and the possibility that one day it may lead to a clinical application," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "Having a marker to detect the development of new primary cancers in patients who have already undergone surgery is crucial."

About the JCA-Mauvernay Award

The JCA-Mauvernay Award is organised jointly by the JCA and Debiopharm to honour innovative fundamental and clinical oncology research and to encourage Japanese scientists to make their work available outside Japan. This is the fifth edition of the ceremony.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

    Debiopharm S.A. Contact         Additional Media Contacts
    Maurice Wagner                  In London
    Director Corporate Affairs      Maitland
    & communication                 Brian Hudspith
    Tel.: +41(0)21-321-01-11        Tel: +44(0)20-7379-5151
    Fax: +41(0)21-321-01-69         bhudspith@maitland.co.uk
    mwagner@debiopharm.com
                                    In New York
                                    Russo Partners, LLC
                                    Martina Schwarzkopf, Ph.D.
                                    Account Executive
                                    Tel: +1-212-845-4292
                                    Fax: +1-212-845-4260
                                    martina.schwarzkopf@russopartnersllc.com



SOURCE Debiopharm Group


'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
3. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
4. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Novel Technology Breaks Through Cancer Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Japan , Dec. 9, 2016 Mitsubishi ... ; President & Representative Director, CEO: Dr. Masayuki ... amyotrophic lateral sclerosis (ALS) given edaravone intravenously in 10-14 ... loss as measured by the ALS Functional Rating Scale-Revised ... International Symposium on ALS/MND in Dublin, ...
(Date:12/9/2016)... DUBLIN , Dec 9, 2016 Research ... Vaccines Market 2016-2020" report to their offering. ... The global travel vaccines market ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...
(Date:12/9/2016)... Dec. 9, 2016  Forge Therapeutics, Inc. today ... Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance ... the treatment of bacterial infections including those caused ... as an attractive antibacterial target for more than ... suitable chemical starting points has hampered its progress. ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... Groth Family Insurance, a Washington-based firm offering ... a charity drive to support the family of Cindy Hendrickson, a local mother ... On October 29th of this year, Cindy Hendrickson swerved to avoid an oncoming ...
(Date:12/9/2016)... Ohio (PRWEB) , ... December 09, 2016 , ... ... of miniature, folded, pharmaceutical inserts and outserts. As a means of expanding ... This addition will enable Flottman to individually code professional inserts (PIs) and patient ...
(Date:12/9/2016)... Yorktown Heights, NY (PRWEB) , ... December 09, 2016 , ... ... on Alcoholism and Drug Dependence, Inc. (NCADD) is recommending the film Whispering ... 29 states and the District of Columbia as an education tool in the war ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... An inventor ... amputees to safely ride all types of amusement park rides. , The patent-pending SAFETY ... unit is easy to use and could be set up in a matter of ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pierre Hotel in New York, NY, on December 3rd, to benefit Holy Name ... attended the annual event, which raised over $1 million - the largest event ...
Breaking Medicine News(10 mins):